IGI Logo

Zydus Lifesciences is currently trading at Rs. 1163.60, up by 19.00 points or 1.66% from its previous closing of Rs. 1144.60 on the BSE.

The scrip opened at Rs. 1139.80 and has touched a high and low of Rs. 1165.45 and Rs. 1122.00 respectively. So far 8396 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1203.20 on 11-Jul-2024 and a 52 week low of Rs. 564.05 on 25-Jul-2023.

Last one week high and low of the scrip stood at Rs. 1198.80 and Rs. 1122.00 respectively. The current market cap of the company is Rs. 115173.54 crore.

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.22% and 6.79% respectively.

Zydus Lifesciences has received approval from Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) to market Bhava, a Bevacizumab biosimilar in different strengths of 100 mg/4 ml and 400 mg/16 ml and used in the treatment of metastatic Colorectal Cancer (mCRC), non-squamous non-small cell lung cancer, metastatic breast cancer, glioblastoma, advanced and/or metastatic renal cell carcinoma and ovarian cancer patients. 

As per a WHO report of 2020, out of the total cancer cases reported in Mexico, breast, prostate, colorectal and thyroid were amongst the common cancer cases registered. Zydus had developed and launched the Bevacizumab biosimilar developed in-house by the research team at the Zydus Research Centre (ZRC) in 2015 in India under the brand name Bryxta. ?Since then, an estimated 50000 patients have been treated with the therapy. With twelve lifesaving biosimilars already launched in the market, Zydus has been bridging the unmet need for affordable therapies in the fight against cancer in India.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.